Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases
Main finding · Symptom-free days over follow-upResult — go to the resultDifference +21.4 days 95% CI 0.95–41.91Authors' conclusion
Vaccinated patients with SARDs were less likely to experience PASC compared with those not fully vaccinated.
Study context
- Population
- Patients with systemic autoimmune rheumatic diseases (SARDs) from a large healthcare system who survived acute SARS-CoV-2 infection (mean age 53 years; 80% female)11% unvaccinated
- Participants
- 280 patients
- Exposure
- Breakthrough infection vs non-breakthrough COVID-19 infection
- Breakthrough infectionn = 116
- Non-breakthrough infectionn = 164reference
- Outcome
- Symptom-free duration and odds of PASC (any symptom lasting ≥28 or 90 days)
Methodological detailssurvey-based, restricted mean survival time, multivariable logistic regression
- Survey-based
- Restricted mean survival time
- Multivariable logistic regression
Main finding
Symptom-free days over follow-up
Difference
+21.4 days
95% CI 0.95–41.91
P = 0.04
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | |
|---|---|---|
| PASC at 28 and 90 daysBreakthrough infectionvs Non-breakthrough infection28 days | 0.49 (0.29–0.83) | |
| PASC at 28 and 90 daysBreakthrough infectionvs Non-breakthrough infection90 days | 0.10 (0.04–0.22) | |
| 0.050.21520Adjusted odds ratio (log scale) |
Symptom profile
- Breakthrough infection had more upper respiratory symptoms; non-breakthrough had more anosmia, dysgeusia and joint pain
Original publication
Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases. Ann Rheum Dis. Published 28 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →